Sabby Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Sabby Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-813	Closed	-$47K	–	376
2016 Q2	$47K	Hold	813	–	–	﹤0.01%	276
2016 Q1	$119K	Sell	813 -352	-30%	-$695	0.01%	273
2015 Q4	$373K	Sell	1,165 -4,877	-81%	-$23.5K	0.02%	255
2015 Q3	$3.78M	Sell	6,042 -820	-12%	-$7.67K	0.16%	103
2015 Q2	$6.81M	Buy	6,862 +3,310	+93%	+$29K	0.25%	76
2015 Q1	$2.62M	Buy	3,552 +158	+5%	+$1.06K	0.11%	121
2014 Q4	$1.82K	Buy	3,394 +41	+1%	+$210	0.06%	132
2014 Q3	$1.69K	Buy	3,353 +1,512	+82%	+$9.29K	0.06%	126
2014 Q2	$1.24M	Buy	1,841 +973	+112%	+$6.19K	0.05%	131
2014 Q1	$628K	Sell	868 -944	-52%	-$5.6K	0.04%	164
2013 Q4	$683K	Buy	+1,812	New	+$7.01K	0.04%	139

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sabby Management's NWBO Position: Q3 2016 in Review

Sabby Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2016, closing a stake of 881,585 shares — an estimated $512K sold.

Sabby Management first reported a position in NWBO in Q2 2013 and held it in 7 quarters. The position peaked at $4.84M in Q1 2016. 54 funds tracked by Wall St. Rank hold NWBO as of Q3 2016.

Sabby Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2016 after selling out during the quarter.
Sabby Management sold 881,585 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2016, an estimated $512K.
Sabby Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 7 quarters.
Sabby Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $4.84M in Q1 2016.
54 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.